AKBA Earnings & Financial Statements
Akebia Therapeutics, Inc.
$0.70
-$0.07(-8.83%)
39
Overall
40
Value
40
Tech
39
Quality
Market Cap
$194.53M
Volume
13.89M
52W Range
$0.80 - $3.20
Target Price
$3.80
AKBA earnings and financial statements: Akebia Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AKBA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $236.20M | $160.18M | $194.62M | $292.48M | $213.58M |
| Cost of revenue | $39.46M | $27.14M | $38.11M | $85.57M | $150.67M |
| Operating income | $23.50M | -$50.47M | -$46.26M | -$80.78M | -$265.32M |
| EBITDA | $21.73M | -$13.76M | -$4.05M | -$43.26M | -$228.37M |
| Net income | -$5.34M | -$69.41M | -$51.92M | -$94.23M | -$282.02M |
| EPS (diluted) | $-0.02 | $-0.33 | $-0.28 | $-0.51 | $-1.70 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $376.56M | $220.67M | $241.70M | $356.05M | $525.60M |
| Total liabilities | $343.95M | $269.86M | $272.29M | $350.82M | $449.09M |
| Shareholders’ equity | $32.61M | -$49.19M | -$30.58M | $5.23M | $76.46M |
| Cash and equivalents | $184.84M | $51.87M | $42.92M | $90.47M | $149.80M |
| Long-term debt | $48.25M | $42.24M | $26.13M | $63.04M | $33.70M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $67.99M | -$40.66M | -$23.38M | -$73.15M | -$252.98M |
| Capital expenditure | -$119.0K | -$33.0K | - | -$114.0K | -$59.0K |
| Free cash flow | $67.70M | -$40.69M | -$23.38M | -$73.27M | -$253.04M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AKBA | $0.70 | -8.8% | 13.89M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Akebia Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW